Thermo Fisher Scientific completes acquisition of PeproTech
05 January 2022 | News
Increases capabilities serving the high growth cell and gene therapy market
image credit- shutterstock
Thermo Fisher Scientific Inc. has completed acquisition of PeproTech for a total cash purchase price of approximately $1.85 billion.
Based in Cranbury, New Jersey, PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors.
Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models.
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering.
PeproTech will become part of the biosciences business within Thermo Fisher and will be integrated into the Life Sciences Solutions Segment.
